Yao Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yao Gao has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Feng Ren
Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China
3 shared publications - Ling Xu
Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing, China
3 shared publications - Sisi Chen
Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
3 shared publications - Xiangying Zhang
Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, China
3 shared publications - Yaling Cao
Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
3 shared publications - Yuan Tian
Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
3 shared publications
Latest Publications
- Open Access
Diagnostic Efficacy of Serological Antibody Detection Tests for Hepatitis Delta Virus: A Systematic Review and Meta-Analysis
Background and Aims Coinfection of hepatitis delta virus (HDV) with hepatitis B virus (HBV) causes the most severe form of viral hepatitis, and the global prevalence of HDV infection is underestimated. Although serological testing of anti-HDV antibodies is widely used in the diagnosis of HDV, its diagnostic efficacy remains unclear. This study aimed to evaluate the diagnostic efficacy of HDV serological tests, the results of which may assist in the diagnosis of HDV. Methods Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. The PubMed, Web of Science and Cochrane Library databases were searched from the beginning to 31 May 2023. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. STATA SE was used for the meta-analysis of the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio. Results Among a total of 1376 initially identified studies, only 12 articles met the final inclusion criteria. The pooled sensitivity and specificity were 1.00 (95% CI: 0.00–1.00) and 0.71 (95% CI: 0.50–0.78) for HDV total antibodies, 0.96 (95% CI: 0.83–0.99) and 0.98 (95% CI: 0.82–1.00) for anti-HDV IgM and 0.95 (95% CI: 0.86–0.98) and 0.96 (95% CI: 0.67–1.00) for anti-HDV IgG. The pooled sensitivity and specificity for HDV serological tests were 0.99 (95% CI: 0.96–1.00) and 0.90 (95% CI: 0.79–0.96). Conclusions This meta-analysis suggests that serological tests have high diagnostic performance in detecting antibodies against HDV, especially in HDV IgM and IgG. However, this conclusion is based on studies of a limited number and quality, and the development of new diagnostic tools with higher precision and reliability is still necessary.
Open AccessDiagnostic Efficacy of Serological Antibody Detection Tests for Hepatitis Delta Virus: A Systematic Review and Meta-Analysis
Background and Aims Coinfection of hepatitis delta virus (HDV) with hepatitis B virus (HBV) causes the most severe form of viral hepatitis, and the global prevalence of HDV infection is underestimated. Although serological testing of anti-HDV antibodies is widely used in the diagnosis of HDV, its diagnostic efficacy remains unclear. This study aimed to evaluate the diagnostic efficacy of HDV serological tests, the results of which may assist in the diagnosis of HDV. Methods Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. The PubMed, Web of Science and Cochrane Library databases were searched from the beginning to 31 May 2023. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. STATA SE was used for the meta-analysis of the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio. Results Among a total of 1376 initially identified studies, only 12 articles met the final inclusion criteria. The pooled sensitivity and specificity were 1.00 (95% CI: 0.00–1.00) and 0.71 (95% CI: 0.50–0.78) for HDV total antibodies, 0.96 (95% CI: 0.83–0.99) and 0.98 (95% CI: 0.82–1.00) for anti-HDV IgM and 0.95 (95% CI: 0.86–0.98) and 0.96 (95% CI: 0.67–1.00) for anti-HDV IgG. The pooled sensitivity and specificity for HDV serological tests were 0.99 (95% CI: 0.96–1.00) and 0.90 (95% CI: 0.79–0.96). Conclusions This meta-analysis suggests that serological tests have high diagnostic performance in detecting antibodies against HDV, especially in HDV IgM and IgG. However, this conclusion is based on studies of a limited number and quality, and the development of new diagnostic tools with higher precision and reliability is still necessary.
- Open Access
- 6 November 2023
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (1) , 118-127
CRISPR/Cas13-assisted carbapenem-resistant Klebsiella pneumoniae detection
- 6 November 2023
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (1) , 118-127
Open AccessCRISPR/Cas13-assisted carbapenem-resistant Klebsiella pneumoniae detection
- Open Access
- 20 February 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (1) , e2177088
CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients
The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications...
- 20 February 2023
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 12 (1) , e2177088
Open AccessCRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients
The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications...